Document is current

Article History

Received: 13 October 2023

Accepted: 16 January 2024

First Online: 9 April 2024

Declarations

:

: MP has served on advisory boards for AstraZeneca and Janssen-Cilag; received a grant from the Danish Cardiovascular Academy funded by the Novo Nordisk Foundation and the Danish Heart Foundation (grant number: CPD5Y-2022004-HF); and received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen-Cilag. MF was a consultant for ProofDx, a startup company creating a point-of-care diagnostic test for COVID-19. MF is an advisor for SIGNAL1, a startup company deploying machine learned models to improve inpatient care. TBS is chief investigator of the Novo Nordisk financed “NUDGE-DM-PERSISTENCE” trial; chief investigator of the Boston Scientific financed “DANLOGIC-HF” trial; chief investigator of the Sanofi Pasteur financed “NUDGE-FLU” trial; chief investigator of the Sanofi Pasteur financed “DANFLU-1” trial; chief investigator of the Sanofi Pasteur financed “DANFLU-2” trial; steering committee member of Boston Scientific sponsored “LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System” trial; steering committee member of the Amgen sponsored GALACTIC-HF trial; steering committee member of the Boehringer Ingelheim financed EASi-KIDNEY trial; Advisory Board: Sanofi Pasteur, Amgen, CSL Seqirus, and GSK; speaker honorarium: Bayer, Novartis, Sanofi Pasteur, GE healthcare and GSK; research grants: Boston Scientific, GE Healthcare, AstraZeneca, Novo Nordisk, and Sanofi Pasteur; consultant appointments: Novo Nordisk, IQVIA, and Parexel.

Free to read: This content has been made available to all.